Author/Authors :
Marco L. Lolli، نويسنده , , Barbara Rolando، نويسنده , , Paolo Tosco، نويسنده , , Shilpi Chaurasia، نويسنده , , Antonella Di Stilo، نويسنده , , Loretta Lazzarato، نويسنده , , Eva Gorassini، نويسنده , , Riccardo Ferracini، نويسنده , , Simonetta Oliaro-Bosso، نويسنده , , Roberta Fruttero، نويسنده , , Alberto Gasco، نويسنده ,
Abstract :
A new series of bisphosphonates bearing either the nitrogen-containing NO-donor furoxan (1,2,5-oxadiazole 2-oxide) system or the related furazan (1,2,5-oxadiazole) in lateral chain has been developed. pKa values and affinity for hydroxyapatite were determined for all the compounds. The products were able to inhibit osteoclastogenesis on RAW 246.7 cells at 10 μM concentration. The most active compounds were further assayed on human PBMC cells and on rat microsomes. Unlike most nitrogen-containing bisphosphonates which target farnesyl pyrophosphate synthase, experimental and theoretical investigations suggest that the activity of our derivatives may be related to different mechanisms. The furoxan derivatives were also tested for their ability to relax rat aorta strips in view of their potential NO-dependent vasodilator properties.
Keywords :
cardiovascular diseases , Bisphosphonates , nitric oxide , Osteoclastogenesis